BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 9753691)

  • 1. Structural basis of inhibitor selectivity in MAP kinases.
    Wang Z; Canagarajah BJ; Boehm JC; Kassisà S; Cobb MH; Young PR; Abdel-Meguid S; Adams JL; Goldsmith EJ
    Structure; 1998 Sep; 6(9):1117-28. PubMed ID: 9753691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
    Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
    Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase.
    Wilson KP; McCaffrey PG; Hsiao K; Pazhanisamy S; Galullo V; Bemis GW; Fitzgibbon MJ; Caron PR; Murcko MA; Su MS
    Chem Biol; 1997 Jun; 4(6):423-31. PubMed ID: 9224565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket.
    Gum RJ; McLaughlin MM; Kumar S; Wang Z; Bower MJ; Lee JC; Adams JL; Livi GP; Goldsmith EJ; Young PR
    J Biol Chem; 1998 Jun; 273(25):15605-10. PubMed ID: 9624152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket.
    Tong L; Pav S; White DM; Rogers S; Crane KM; Cywin CL; Brown ML; Pargellis CA
    Nat Struct Biol; 1997 Apr; 4(4):311-6. PubMed ID: 9095200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution.
    Eyers PA; Craxton M; Morrice N; Cohen P; Goedert M
    Chem Biol; 1998 Jun; 5(6):321-8. PubMed ID: 9653550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis for p38 protein kinase inhibitor specificity.
    Lisnock J; Tebben A; Frantz B; O'Neill EA; Croft G; O'Keefe SJ; Li B; Hacker C; de Laszlo S; Smith A; Libby B; Liverton N; Hermes J; LoGrasso P
    Biochemistry; 1998 Nov; 37(47):16573-81. PubMed ID: 9843424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin activates p38 mitogen-activated protein (MAP) kinase via a MAP kinase kinase (MKK) 3/MKK 6 pathway in vascular smooth muscle cells.
    Igarashi M; Yamaguchi H; Hirata A; Daimon M; Tominaga M; Kato T
    Eur J Clin Invest; 2000 Aug; 30(8):668-77. PubMed ID: 10964158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding.
    Frantz B; Klatt T; Pang M; Parsons J; Rolando A; Williams H; Tocci MJ; O'Keefe SJ; O'Neill EA
    Biochemistry; 1998 Sep; 37(39):13846-53. PubMed ID: 9753474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site.
    Young PR; McLaughlin MM; Kumar S; Kassis S; Doyle ML; McNulty D; Gallagher TF; Fisher S; McDonnell PC; Carr SA; Huddleston MJ; Seibel G; Porter TG; Livi GP; Adams JL; Lee JC
    J Biol Chem; 1997 May; 272(18):12116-21. PubMed ID: 9115281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.
    Jackson JR; Bolognese B; Hillegass L; Kassis S; Adams J; Griswold DE; Winkler JD
    J Pharmacol Exp Ther; 1998 Feb; 284(2):687-92. PubMed ID: 9454815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p38 mitogen-activated protein kinase and c-jun-NH2-terminal kinase regulate RANTES production by influenza virus-infected human bronchial epithelial cells.
    Kujime K; Hashimoto S; Gon Y; Shimizu K; Horie T
    J Immunol; 2000 Mar; 164(6):3222-8. PubMed ID: 10706714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour necrosis factor-alpha-induced phosphorylation and activation of cytosolic phospholipase A2 are abrogated by an inhibitor of the p38 mitogen-activated protein kinase cascade in human neutrophils.
    Waterman WH; Molski TF; Huang CK; Adams JL; Sha'afi RI
    Biochem J; 1996 Oct; 319 ( Pt 1)(Pt 1):17-20. PubMed ID: 8870643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion.
    Simon C; Goepfert H; Boyd D
    Cancer Res; 1998 Mar; 58(6):1135-9. PubMed ID: 9515796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase.
    Kumar S; Jiang MS; Adams JL; Lee JC
    Biochem Biophys Res Commun; 1999 Oct; 263(3):825-31. PubMed ID: 10512765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
    Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
    J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils.
    Kankaanranta H; De Souza PM; Barnes PJ; Salmon M; Giembycz MA; Lindsay MA
    J Pharmacol Exp Ther; 1999 Aug; 290(2):621-8. PubMed ID: 10411570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles of ERK1/2 and p38 MAP kinases in the preventive mechanisms of mushroom Phellinus linteus against the inhibition of gap junctional intercellular communication by hydrogen peroxide.
    Cho JH; Cho SD; Hu H; Kim SH; Lee SK; Lee YS; Kang KS
    Carcinogenesis; 2002 Jul; 23(7):1163-9. PubMed ID: 12117774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.